Allakos Inc.
ALLKDelisted May 15, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001564824
Allakos Inc. was delisted on May 15, 2025; its insiders filed their last Form 4 on May 19, 2025; 64 institutions reported holding it in 13F filings for Q1 2025, worth $14.1M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:32 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 27, 2025 | Jan 16, 2024 | Mar 6, 2023 | Mar 1, 2022 | Mar 1, 2021 |
| Operating expenses | $122.2M | $196.1M | $322.4M | $271.5M | $157.1M |
| Research and development | $79.9M | $150.9M | $265.1M | $196.3M | $105.5M |
| Selling, general and administrative | $38.8M | $45.1M | $57.3M | $75.1M | $51.5M |
| Operating income | -$122.2M | -$196.1M | -$322.4M | -$271.5M | -$157.1M |
| Net income | -$115.8K | -$185.7M | -$320.0M | -$269.9M | -$153.5M |
| EPS, basic | $-1.30 | $-2.14 | $-5.06 | – | – |
| EPS, diluted | $-1.30 | $-2.14 | $-5.06 | – | – |
| Weighted shares, basic | 88.8M | 86.8M | 63.3M | – | – |
| Weighted shares, diluted | 88.8M | 86.8M | 63.3M | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 27, 2025 | Jan 16, 2024 | Mar 6, 2023 | Mar 1, 2022 | Mar 1, 2021 |
| Cash and equivalents | $17.8M | $66.4M | $87.2M | $152.8M | $207.2M |
| Short-term investments | $63.1M | $104.4M | $192.6M | $271.4M | $451.8M |
| Total current assets | $85.6M | $179.9M | $308.8M | $451.6M | $669.3M |
| Property, plant and equipment | $10.8M | $33.4M | $39.1M | $43.1M | $8.35M |
| Total assets | $96.6M | $243.6M | $386.4M | $534.8M | $719.6M |
| Accounts payable | $5.49M | $1.76M | $4.83M | $13.7M | $14.0M |
| Total current liabilities | $17.8M | $36.6M | $30.0M | $40.2M | $22.4M |
| Total liabilities | $17.8M | $74.8M | $76.0M | $89.3M | $65.2M |
| Shareholders' equity | $78.8M | $168.8M | $310.4M | $445.5M | $654.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 27, 2025 | Jan 16, 2024 | Mar 6, 2023 | Mar 1, 2022 | Mar 1, 2021 |
| Operating cash flow | -$93.6M | -$116.5M | -$280.0M | -$207.9M | -$113.9M |
| Capital expenditures | $119.0K | $592.0K | $8.33M | $33.2M | $630.0K |
| Free cash flow | -$93.7M | -$117.1M | -$288.3M | -$241.1M | -$114.6M |
| Depreciation and amortization | $7.72M | $6.14M | $7.07M | $2.31M | $1.54M |
| Stock-based compensation | $25.6M | $41.2M | $43.2M | $50.8M | $33.4M |
| Investing cash flow | $44.8M | $93.2M | $71.7M | $143.2M | $3.90M |
| Financing cash flow | $177.0K | $2.53M | $141.9M | $10.3M | $278.8M |
| Net change in cash | -$48.7M | -$20.8M | -$66.4M | -$54.4M | $168.8M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.